BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Copanlisib
|
Drug: Copanlisib (Aliqopa, BAY80-6946)
BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
|
Outcome Measures
Primary Outcome Measures
- Characterize safety, tolerability + pharmacokinetics, to determine the maximum tolerated dose of BAY80-6946 administered 1x weekly for 3 weeks, every 4weeks, as a 1h-intravenous infusion. Evaluate biomarkers that may be predictive of tumor response. [2 years]
Secondary Outcome Measures
- Determine the effects of BAY80-6946 on blood glucose and insulin, and its safety in patients with type I or II diabetes. [2 years]
- Evaluate for early signs of efficacy in expansion cohorts [2 years]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age >/= 18 years.
-
Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases
-
At least one measurable lesion or evaluable disease
-
Life expectancy of at least 12 weeks
-
ECOG Performance Status of 0, 1 or 2
-
PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]. Low-dose aspirin is permitted (</= 100 mg daily).
-
Adequate bone marrow, liver and renal function
-
Ability to understand and to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures
Exclusion Criteria:
-
History of cardiac disease congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).
-
Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level
125 mg/dL at screening, or HbA1c 7%
-
Active clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0)
-
History of having received allogeneic organ transplant
-
Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.
-
Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Scottsdale | Arizona | United States | 85258 | |
| 2 | Pittsburgh | Pennsylvania | United States | 15213 | |
| 3 | San Antonio | Texas | United States | 78229-3307 |
Sponsors and Collaborators
- Bayer
Investigators
- Study Director: Bayer Study Director, Bayer
Study Documents (Full-Text)
None provided.More Information
Publications
- 12871